Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Vs. Gopaul"'
Publisher Summary This chapter presents a simple, sensitive, and direct reverse phase (RP) liquid chromatography-mass spectrometry (LC-MS) method for the on-line identification and characterization of Ribavirin (1-β-D-ribofuranosyl-1H-1,2,4-triazole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83f766f684c410c44ad3deb787cf7365
https://doi.org/10.1016/s1464-3456(05)80013-4
https://doi.org/10.1016/s1464-3456(05)80013-4
Kniha
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Göpel SO; Global Patient Safety BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden. Sven.gopel@astrazeneca.com., Adingupu D; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wang J; College of Future Technology, Peking University, Beijing, 100871, China., Semenova E; Data Sciences and Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.; Imperial College London, School of Public Health, Department of Epidemiology and Biostatistics, London, United Kingdom., Behrendt M; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jansson-Löfmark R; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ahlström C; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jönsson-Rylander AC; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Gopaul VS; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Esterline R; Late CVRM, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA., Gan LM; Ribocure Pharmaceuticals AB, Gothenburg, Sweden & SuZhou Ribo Life Science Co. Ltd., Gothenburg, Sweden.; Department of Cardiology, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden., Xiao RP; College of Future Technology, Peking University, Beijing, 100871, China.
Publikováno v:
Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Nov 15; Vol. 23 (1), pp. 408. Date of Electronic Publication: 2024 Nov 15.
Autor:
Kabir M; Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Bergman RN; Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Porter J; Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Stefanovski D; University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA., Paszkiewicz RL; Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Piccinini F; Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Woolcott OO; Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Yang H; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Gopaul VS; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Stiles L; Department of Endocrinology, David Geffen School of Medicine at the University of California, Los Angeles, California, USA., Kolka CM; Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Publikováno v:
Obesity (Silver Spring, Md.) [Obesity (Silver Spring)] 2023 Jul; Vol. 31 (7), pp. 1798-1811. Date of Electronic Publication: 2023 May 23.
Autor:
Jurva U; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.) ulrik.jurva@astrazeneca.com., Weidolf L; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Sandinge AS; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Leandersson C; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Ekdahl A; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Li XQ; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Antonsson T; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Sundell J; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Westerlund K; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Amilon C; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Inghardt T; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.)., Gopaul VS; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Apr; Vol. 51 (4), pp. 464-479. Date of Electronic Publication: 2023 Jan 18.
Autor:
Bhattacharya C; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Sandinge AS; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Bragg RA; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Heijer M; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Yan J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Andersson LC; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Jurva U; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Pelay-Gimeno M; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Vaes WHJ; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., de Ligt RAF; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Gränfors M; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Amilon C; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Lindstedt EL; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Menakuru SR; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Garkaviy P; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Weidolf L; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.)., Gopaul VS; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (A.-S.S., J.Y., U.J., L.C.A., V.S.G.); Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences (M.H.); and Early Product Development, Pharmaceutical Sciences (M.G.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); TNO, Leiden, The Netherlands (M.P.-G., W.H.J.V., R.A.F.d.L.); Quotient Sciences, Nottingham, United Kingdom (S.R.M.); Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.G.); and Formerly BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (L.W., C.A., E.-L.L.) sashi.gopaul@astrazeneca.com.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Apr; Vol. 51 (4), pp. 451-463. Date of Electronic Publication: 2023 Jan 13.
Autor:
Pieterman EJ; The Netherlands Organisation for Applied Scientific Research (TNO), Metabolic Health Research, Leiden, Netherlands., Princen HMG; The Netherlands Organisation for Applied Scientific Research (TNO), Metabolic Health Research, Leiden, Netherlands., Jarke A; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Nilsson R; Early Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Cavallin A; Early Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Bergenholm L; Early Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Henricsson M; Early Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Gopaul VS; Early Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Agrawal R; Global Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Nissen SE; Department of Cardiovascular Medicine and Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, OH, United States., Hurt-Camejo E; Early Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Publikováno v:
Frontiers in pharmacology [Front Pharmacol] 2021 Aug 16; Vol. 12, pp. 681455. Date of Electronic Publication: 2021 Aug 16 (Print Publication: 2021).
Autor:
Gopaul VS; Early Research and Development Cardiovascular Renal and Metabolism, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (V.S.G, A.V., T.B.A, C.H.); CVRM Late Clinical, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (F.E.); Ardea Biosciences, San Diego, CA, USA (C.A.L.); Clinical Pharmacology & Safety Sciences & AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (S.J.) sashi.gopaul@astrazeneca.com., Vildhede A; Early Research and Development Cardiovascular Renal and Metabolism, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (V.S.G, A.V., T.B.A, C.H.); CVRM Late Clinical, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (F.E.); Ardea Biosciences, San Diego, CA, USA (C.A.L.); Clinical Pharmacology & Safety Sciences & AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (S.J.)., Andersson TB; Early Research and Development Cardiovascular Renal and Metabolism, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (V.S.G, A.V., T.B.A, C.H.); CVRM Late Clinical, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (F.E.); Ardea Biosciences, San Diego, CA, USA (C.A.L.); Clinical Pharmacology & Safety Sciences & AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (S.J.)., Erlandsson F; Early Research and Development Cardiovascular Renal and Metabolism, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (V.S.G, A.V., T.B.A, C.H.); CVRM Late Clinical, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (F.E.); Ardea Biosciences, San Diego, CA, USA (C.A.L.); Clinical Pharmacology & Safety Sciences & AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (S.J.)., Lee CA; Early Research and Development Cardiovascular Renal and Metabolism, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (V.S.G, A.V., T.B.A, C.H.); CVRM Late Clinical, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (F.E.); Ardea Biosciences, San Diego, CA, USA (C.A.L.); Clinical Pharmacology & Safety Sciences & AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (S.J.)., Johansson S; Early Research and Development Cardiovascular Renal and Metabolism, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (V.S.G, A.V., T.B.A, C.H.); CVRM Late Clinical, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (F.E.); Ardea Biosciences, San Diego, CA, USA (C.A.L.); Clinical Pharmacology & Safety Sciences & AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (S.J.)., Hilgendorf C; Early Research and Development Cardiovascular Renal and Metabolism, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (V.S.G, A.V., T.B.A, C.H.); CVRM Late Clinical, AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (F.E.); Ardea Biosciences, San Diego, CA, USA (C.A.L.); Clinical Pharmacology & Safety Sciences & AstraZeneca Biopharmaceuticals R&D Gothenburg, Mölndal, Sweden (S.J.).
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2021 Aug; Vol. 378 (2), pp. 108-123. Date of Electronic Publication: 2021 Jun 01.
Autor:
Gopaul VS; Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Pieterman EJ; The Netherlands Organization for Applied Scientific Research (TNO)-Metabolic Health Research, Leiden, Netherlands., Princen HMG; The Netherlands Organization for Applied Scientific Research (TNO)-Metabolic Health Research, Leiden, Netherlands., Bergenholm L; Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Lundborg E; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Cavallin A; Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Johansson MJ; Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hawthorne G; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Björkbom A; Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hammarberg M; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden., Li X; Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jarke A; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Bright J; New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK., Svensson L; Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jansson-Löfmark R; Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Abrahamsson B; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden. Electronic address: bertil.abrahamsson@AstraZeneca.com., Agrawal R; Global Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hurt-Camejo E; Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2021 Jun 01; Vol. 161, pp. 105776. Date of Electronic Publication: 2021 Mar 02.